VTR(SZ:300381) Xin Lang Cai Jing·2026-01-16 02:37Core Viewpoint - Yidoli's stock price has shown fluctuations with a recent decline, while the company has experienced mixed financial performance in terms of revenue and net profit [1][2]. Group 1: Stock Performance - As of January 16, Yidoli's stock price decreased by 2.13%, trading at 6.89 CNY per share with a total market capitalization of 3.383 billion CNY [1]. - Year-to-date, Yidoli's stock has increased by 5.67%, with a 1.62% rise over the last five trading days and an 8.85% increase over the last 20 days, while it has seen a slight decline of 0.72% over the past 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Yidoli reported a revenue of 613 million CNY, reflecting a year-on-year growth of 0.77%, while the net profit attributable to shareholders was 18.204 million CNY, which represents a significant decrease of 57.47% compared to the previous year [2]. - Since its A-share listing, Yidoli has distributed a total of 359 million CNY in dividends, with 125 million CNY distributed over the last three years [3]. Group 3: Company Overview - Yidoli, established on September 3, 1991, and listed on January 28, 2014, is located in Zhuhai, Guangdong Province, and specializes in the research, production, and sales of biological enzyme preparations, steroid hormone raw materials, plant extracts, and animal nutrition products [2]. - The company's main business revenue composition includes biological enzyme preparations (83.94%), plant extracts (8.34%), feed and feed additives (6.78%), and other products (0.95%) [2]. - Yidoli is classified under the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and raw material drug sectors, and is associated with concepts such as raw materials, vitamins, small-cap stocks, biological manufacturing, and synthetic biology [2].